GTC
COLL icon

Ghost Tree Capital’s Collegium Pharmaceutical COLL Stock Holding History

Ghost Tree Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-375,000
Closed -$3.77M – 70
2017
Q1 		$3.77M Buy
+375,000
New +$5.57M 0.7% 48

Other funds holding COLL

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

Ghost Tree Capital's COLL Position: Q2 2017 in Review

Ghost Tree Capital sold out of Collegium Pharmaceutical (COLL) in Q2 2017, closing a stake of 375,000 shares — an estimated $3.77M sold.

Ghost Tree Capital first reported a position in COLL in Q1 2017 and held it in 1 quarter. The position peaked at $3.77M in Q1 2017. 72 funds tracked by Wall St. Rank hold COLL as of Q2 2017.

  • Ghost Tree Capital reported no remaining Collegium Pharmaceutical position as of Q2 2017 after selling out during the quarter.
  • Ghost Tree Capital sold 375,000 Collegium Pharmaceutical shares in Q2 2017, an estimated $3.77M.
  • Ghost Tree Capital first reported a position in Collegium Pharmaceutical in Q1 2017 and held it in 1 quarter.
  • Ghost Tree Capital's Collegium Pharmaceutical position peaked at $3.77M in Q1 2017.
  • 72 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2017.

Based on Ghost Tree Capital's 13F filing for Q2 2017, filed 14 Aug 2017.